Evidence map›Paper›PMID 25970292›Full record

ArticlePloS one2015

Novel antimicrobial peptides with high anticancer activity and selectivity.

Hung-Lun Chu, Bak-Sau Yip, Kuan-Hao Chen, Hui-Yuan Yu, Ya-Han Chih, Hsi-Tsung Cheng, Yu-Ting Chou, Jya-Wei Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Prediction of Antibacterial Peptides againstMolecules (Basel, Switzerland) · 2022
    Article
  13. A review on antimicrobial peptides databases and the computational tools.Database : the journal of biological databases and curation · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hung-Lun ChuInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan.
Bak-Sau YipInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan; Department of Neurology, National Taiwan University Hospital Hsinchu Branch, Hsinchu, 300, Taiwan.
Kuan-Hao ChenInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan.
Hui-Yuan YuInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan.
Ya-Han ChihInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan.
Hsi-Tsung ChengInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan.
Yu-Ting ChouInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan.
Jya-Wei ChengInstitute of Biotechnology and Department of Medical Science, National Tsing Hua University, Hsinchu, 300, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe a strategy to boost anticancer activity and reduce normal cell toxicity of short antimicrobial peptides by adding positive charge amino acids and non-nature bulky amino acid β-naphthylalanine residues to their termini. Among the designed peptides, K4R2-Nal2-S1 displayed better salt resistance and less toxicity to hRBCs and human fibroblast than Nal2-S1 and K6-Nal2-S1. Fluorescence microscopic studies indicated that the FITC-labeled K4R2-Nal2-S1 preferentially binds cancer cells and causes apoptotic cell death. Moreover, a significant inhibition in human lung tumor growth was observed in the xenograft mice treated with K4R2-Nal2-S1. Our strategy provides new opportunities in the development of highly effective and selective antimicrobial and anticancer peptide-based therapeutics.

Indexed as

AnimalsAnti-Bacterial AgentsAntibiotics, AntineoplasticAntimicrobial Cationic PeptidesApoptosisCell Line, TumorEscherichia coliHumansLung NeoplasmsMaleMice, Inbred BALB CMice, NudeMicrobial Sensitivity TestsPseudomonas aeruginosaStaphylococcus aureusXenograft Model Antitumor AssaysAnti-Bacterial AgentsAntibiotics, AntineoplasticAntimicrobial Cationic Peptides

Identifiers

PMID25970292
PMCPMC4430538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.